HPV assays validated for primary cervical cancer screening

Home

Related articles

Self-sampling to reach non-participating women

J Bonde & D Ejegod
Interview Marc Arbyn

M Arbyn
Primary hrHPV population screening for cervical cancer in the Netherlands

K M Holtzer-Goor, E Brouwer, N van der Veen & S A van Dijk
HPV testing on self-samples: the evidence of Today

M Arbyn, S Smith & P Castle
VALGENT 4

J Bonde & D Ejegod
HPV-based cervical cancer screening in US

N Wentzensen & M Schiffman
Longitudinal performance in cervical cancer screening of an HPV mRNA assay for detection of severe lesions occurring up to seven years later

J Dillner & O Forslund
Italian consensus on cervical cancer screening in hpv vaccinated woman

P Giorgi Rossi, M T Sandri, L Mariani & F Carozzi
Core elements of the new HPV-based cervical cancer screening programme in Italy

G Ronco
Slovenian HPV Prevalence Study and VALGENT 3 framework

M Poljak & A Oštrbenk
Integrating HPV-screening and HPV vaccination in Central and Eastern Europe

M Poljak
The BD Onclarity HPV assay: Key data pointing to clinical validity

M H Stoler & T C Wright Jr
HPV screening: DNA- versus RNAbased HPV Tests

T Iftner
VALGENT2 contribution towards hpv-primary screening in scotland

K Cuschieri & R Bhatia
Experiences with the use of HPV testing in cervical cancer screening in Sweden

J Dillner & M Elfström
Xpert HPV: Basis and key results in best trials

L Denny, R Saidu & L Kuhn
HPV DNA or HPV E6/E7 mRNA assays?

T Iftner
Australia on-track to be the first country to achieve cervical cancer elimination

K Canfell, M Hall, K Simms, M Smith & M Saville
Primary HPV screening in the US with the Cobas® assay

A C Cohen & W K Huh
The concept of HPV tests adapted to emerging economies

J Jeronimo

HOME
Published material
Remembering our colleagues
About us
Contact us

Login

Change email Change password Activate service

Did you forget your password?

Do you want to subscribe?

Legal notice Privacy Policy

Copyright © 2022 HPV World All rights reserved